Related Experiment Video
Updated: Jun 10, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
Volume overload and cardiorenal syndromes
1Department of Nephrology, St Bortolo Hospital, Vicenza, Italy. cronco@goldnet.it
Insights
Cardiorenal syndromes (CRSs) involve complex heart and kidney interactions. Understanding the 5 subtypes of CRS is crucial for accurate diagnosis and effective treatment strategies.
Area of Science:
- Cardiology
- Nephrology
- Pathophysiology
Background:
- Cardiorenal syndromes (CRSs) represent bidirectional pathophysiologic interactions between the heart and kidneys.
- Dysfunction in one organ can precipitate dysfunction in the other, necessitating a clear classification system.
Purpose of the Study:
- To outline the current classification of cardiorenal syndromes, encompassing 5 distinct subtypes.
- To emphasize the importance of understanding the primary and secondary pathologies, time frames, and organ dysfunction in CRS.
Main Methods:
- Classification based on the primary organ affected, the nature of dysfunction (acute/chronic), and the resulting impact on the other organ.
- Identification of 5 subtypes: Type 1 (heart to kidney, acute), Type 2 (heart to kidney, chronic), Type 3 (kidney to heart, acute), Type 4 (kidney to heart, chronic), and Type 5 (systemic insult).
Main Results:
- Type 1 CRS: Acute cardiac dysfunction leading to acute kidney injury.
- Type 2 CRS: Chronic cardiac dysfunction causing progressive chronic kidney disease.
- Type 3 CRS: Acute renal dysfunction leading to acute cardiac disorder.
- Type 4 CRS: Chronic kidney disease contributing to cardiac dysfunction and adverse cardiovascular events.
- Type 5 CRS: Systemic conditions (e.g., sepsis) causing simultaneous cardiac and renal dysfunction.
Conclusions:
- Biomarkers aid in characterizing CRS subtypes and guiding treatment timing and effectiveness.
- Understanding CRS subtypes and underlying mechanisms, including fluid status, is vital for clinical management and future research stratification.
Abstract:
To include the vast array of interrelated derangements and to stress the bidirectional nature of the heart-kidney interactions, the classification of the cardiorenal syndrome today includes 5 subtypes whose terminology reflects their primary and secondary pathology, time frame, and the presence of concomitant cardiac and renal dysfunction. Cardiorenal syndromes (CRSs) are pathophysiologic disorders of the heart and kidneys whereby acute or chronic dysfunction of one organ may induce acute or chronic dysfunction of the other. Type 1 CRS reflects an abrupt worsening of cardiac function leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function causing progressive chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function causing acute cardiac disorder. Type 4 CRS describes a state of chronic kidney disease contributing to decreased cardiac function, cardiac hypertrophy, and/or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (eg, sepsis) simultaneously causing both cardiac and renal dysfunction. Biomarkers can help characterize the subtypes of CRS as well as suggest the timing of treatment initiation and its likely effectiveness. The identification of patients and the pathophysiologic mechanisms underlying each syndrome subtype, including fluid overload or, in general, altered conditions of fluid status, can help physicians understand clinical derangements, provide the rationale for management strategies, and allow the design of future clinical trials with more accurate selection and stratification of the population under investigation.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure Drugs: Diuretics
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VI: Adjunct Therapies
